A board to discuss future MS therapies in early stage (Phase I or II) trials.


Postby marcopolo » Fri Jul 05, 2013 10:41 am

Etifoxine to target, a protein referred to as mitochondrial translocator protein (TSPO), had been previously identified but not linked to MS, an autoimmune disease that strips the protective fatty coating off nerve fibers of the brain and spinal cord.
Family Member
Posts: 29
Joined: Fri Apr 12, 2013 4:18 pm


Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service